Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2051250084) titled 'Phase 1 Clinical study of KA-2301' on Aug. 5.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), active control, crossover assignment, other
Primary Sponsor: Tabata Toshiyuki
Condition:
Healthy volunteer
Intervention:
[Two-drug, Three-stage crossover study]
A single oral dose of KA-2301(2 mg) or ReQuip CR (2 mg) will be administered under fasted conditions, or A single oral dose of KA-2301 (2 mg) after meals....
Recruitment Status: Recruiting
Phase: 1
Date of First Enrollment: 05/08/2025
Target Sample Size: 24
To know more, visit https://jrct.mhlw.go.j...